keyword
MENU ▼
Read by QxMD icon Read
search

leiomyosarcoma therapy

keyword
https://www.readbyqxmd.com/read/29417238/options-for-adjuvant-therapy-for-uterine-leiomyosarcoma
#1
REVIEW
Claire F Friedman, Martee L Hensley
Uterine leiomyosarcoma (uLMS) is a rare disease; in the data from the SEER database, 3165 cases of uLMS were diagnosed between January 2000 and December 2012. While a majority of patients (60%) are diagnosed with early stage disease, recurrence rates are high. Five-year disease-specific survival is 76% for patients with FIGO stage I and 60% for patients with FIGO stage II disease. Adjuvant treatments, including radiation therapy, chemotherapy, and combined modality approaches, have been explored with the goal of demonstrating improved survival...
February 8, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29395283/a-rare-primary-leiomyosarcoma-of-the-parotid-gland-a-case-report-and-literature-review
#2
Lauren E Yue, Muhammad Qazi, Kimberly Kiplagat, Fred M Baik, Azita Khorsandi, Margaret Brandwein-Weber, Mark Urken
BACKGROUND: Leiomyosarcoma of the head and neck region is very rare. Primary parotid leiomyosarcoma has only been reported nine times in the medical literature. METHODS: A 68-year-old female presented with a left facial mass. Physical examination revealed a firm immobile mass at the level of the left parotid tail. No facial nerve dysfunction or palpable adenopathy was noted at the time of presentation. This patient underwent a superficial parotidectomy with a facial nerve dissection and left selective neck dissection...
January 27, 2018: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/29391915/primary-renal-leiomyosarcoma-presenting-with-subcutaneous-and-osseous-metastases-staging-and-follow-up-with-18f-fdg-pet-ct
#3
William Makis, Fadi Brimo, Stephan Probst
A 60 year old woman who presented with multiple small subcutaneous nodules in the upper back and arms, was referred for an [18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) after histological evaluation revealed metastatic leiomyosarcoma of unknown origin. The PET/CT showed multiple 18F-FDG-avid subcutaneous nodules, bone lesions, as well as a large left renal mass, which was biopsied to confirm a primary renal leiomyosarcoma arising from the renal parenchyma...
February 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29387393/denosumab-as-a-potential-therapeutic-option-for-leiomyosarcoma-with-osteoclast-like-giant-cells-a-case-report
#4
Taro Sasaki, Hiroyuki Kawashima, Takashi Ariizumi, Tetsuro Yamagishi, Naoki Oike, Hajime Umezu, Shyoichi Inagawa, Tetsuo Hotta, Naoto Endo, Akira Ogose
Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery...
January 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29355969/primary-liver-sarcomas-in-the-modern-era-resection-or-transplantation
#5
Ioannis T Konstantinidis, Carolijn Nota, Zeljka Jutric, Philip Ituarte, Warren Chow, Peiguo Chu, Gagandeep Singh, Susanne G Warner, Laleh G Melstrom, Yuman Fong
BACKGROUND AND OBJECTIVES: Primary liver sarcomas (PLS) are rare. Published series are limited by small numbers of patients. METHODS: We reviewed the National Cancer Database (2004-2014) for patients who underwent surgical resection of PLS. RESULTS: Of 237 patients identified, the majority were female (60.8%), with median age of 52 years. Histologies were: epithelioid hemangioendothelioma (n = 67), angiosarcoma (n = 64), leiomyosarcoma (n = 33), embryonal rhabdomyosarcoma (n = 31), carcinosarcoma (n = 16), giant cell sarcoma (n = 14), spindle cell sarcoma (n = 12)...
January 22, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29354331/pazopanib-mediated-long-term-disease-stabilization-after-local-recurrence-and-distant-metastasis-of-primary-intracranial-leiomyosarcoma-a-case-report-on-the-efficacy-of-pazopanib-as-a-salvage-therapy
#6
Yasuhiro Kawabata, Tomokazu Aoki, Tetsurou Yamamoto, Hisateru Yasui, Satoru Sawai, Shunichi Fukuda, Satoru Kawarazaki, Tetsuya Tsukahara
Primary intracranial leiomyosarcoma (LMS) is an extremely rare tumor of the central nervous system. Only sporadic case reports have been published, and therefore data regarding long-term prognosis remain scarce. A 76-year-old woman presented with a right parietal mass, which had grown rapidly in the month prior to admission. Neuroimaging showed a resemblance to intraosseous meningioma. Gross total resection of the tumor was achieved, and histological diagnosis confirmed LMS. Because positron emission tomography (PET) with fluorodeoxyglucose (FDG) just after the resection showed no abnormal uptake, we diagnosed the tumor as primary intracranial LMS...
January 2018: NMC Case Report Journal
https://www.readbyqxmd.com/read/29321523/integrative-genomic-and-transcriptomic-analysis-of-leiomyosarcoma
#7
Priya Chudasama, Sadaf S Mughal, Mathijs A Sanders, Daniel Hübschmann, Inn Chung, Katharina I Deeg, Siao-Han Wong, Sophie Rabe, Mario Hlevnjak, Marc Zapatka, Aurélie Ernst, Kortine Kleinheinz, Matthias Schlesner, Lina Sieverling, Barbara Klink, Evelin Schröck, Remco M Hoogenboezem, Bernd Kasper, Christoph E Heilig, Gerlinde Egerer, Stephan Wolf, Christof von Kalle, Roland Eils, Albrecht Stenzinger, Wilko Weichert, Hanno Glimm, Stefan Gröschel, Hans-Georg Kopp, Georg Omlor, Burkhard Lehner, Sebastian Bauer, Simon Schimmack, Alexis Ulrich, Gunhild Mechtersheimer, Karsten Rippe, Benedikt Brors, Barbara Hutter, Marcus Renner, Peter Hohenberger, Claudia Scholl, Stefan Fröhling
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that LMS tumors are characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 and RB1, widespread DNA copy number alterations including chromothripsis, and frequent whole-genome duplication. Furthermore, we detect alternative telomere lengthening in 78% of cases and identify recurrent alterations in telomere maintenance genes such as ATRX, RBL2, and SP100, providing insight into the genetic basis of this mechanism...
January 10, 2018: Nature Communications
https://www.readbyqxmd.com/read/29321409/pulmonary-embolism-caused-by-intravenous-leiomyosarcoma-of-the-lower-limb
#8
Soichiro Kado, Masahide Goto, Hidetsugu Yamao, Toru Tsukada, Masataka Sato, Yoshifumi Uekusa
Pulmonary embolism (PE) is usually caused by thrombosis or tumor. We report the long-term survival of a patient with PE due to a leiomyosarcoma in the deep vein. A 71-year-old woman complained of dyspnea and swelling of the left lower limb. Computed tomography revealed filling defects in the pulmonary arteries and deep vein. She was diagnosed with PE caused by venous thrombosis and treated with anticoagulant therapy. Her symptoms were prolonged, and D-dimer tests remained negative. Biopsy of the substance in the deep vein revealed leiomyosarcoma...
January 11, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29312765/primary-breast-leiomyosarcoma-and-synchronous-homolateral-lung-cancer-a-case-report
#9
Alberto Testori, Stefano Meroni, Emanuele Voulaz, Marco Alloisio, Rita De Sanctis, Paola Bossi, Umberto Cariboni, Matilde De Simone, Ugo Cioffi
Radiological and histological features of breast leiomyosarcoma can mimic a wide variety of other breast lesions, such as mesenchymal tumors, breast lymphomas, poorly differentiated carcinomas and metaplastic breast carcinomas. The authors present the case of a 62-year-old woman with a primary breast leiomyosarcoma with synchronous ipsilateral lung adenocarcinoma. The latter was an incidental finding during pre-surgical staging examinations. Clinicopathological, immunophenotypic and imaging features cancer are described...
December 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29261005/efficacy-and-safety-of-apatinib-monotherapy-in-advanced-bone-and-soft-tissue-sarcoma-an-observational-study
#10
Baorang Zhu, Jing Li, Qiaosheng Xie, Liyan Diao, Lvhua Gai, Wuwei Yang
Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61...
December 20, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29251679/morcellation-in-gynecologic-oncology
#11
Eva Chalas
PURPOSE OF REVIEW: Morcellation of uteri with unsuspected malignancies has been the focus of reports for decades. More intensive evaluation of clinical outcomes and evaluation of impact of changes in practice has occurred since the release of FDA statement advising against the use of power morcellators. The review summarizes some of the most relevant publications on this topic. RECENT FINDINGS: The Society of Gynecologic Oncology and the American College of Obstetricians and Gynecologists concur that symptomatic women should undergo appropriate evaluation, morcellation should not be performed whenever malignancy is suspected or diagnosed, and acknowledge the limitations of diagnostic testing currently available to detect leiomyosarcoma...
February 2018: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29237802/phase-1-dose-escalation-study-of-anti-ctla-4-antibody-ipilimumab-and-lenalidomide-in-patients-with-advanced-cancers
#12
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M Tsimberidou, Jennifer J Wheler, David S Hong, Aung Naing, Gerald S Falchook, Michelle A Fanale, Maria E Cabanillas, Filip Janku
Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxicities (DLT) of the anti-CTLA-4 antibody ipilimumab (1.5-3mg/kg intravenously every 28 days x 4) and lenalidomide (10-25mg orally daily for 21 of 28 days until disease progression or unacceptable toxicity) in advanced cancers...
December 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29216884/intensity-modulated-radiation-therapy-and-surgery-for-management-of-retroperitoneal-sarcomas-a-single-institution-experience
#13
Pippa F Cosper, Jeffrey Olsen, Todd DeWees, Brian A Van Tine, William Hawkins, Jeff Michalski, Imran Zoberi
BACKGROUND: Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important component of multidisciplinary treatment. All retrospective series thus far included patients treated with older radiation therapy (RT) techniques including 2D and 3DRT. Intensity modulated radiation therapy (IMRT) allows for selective dose escalation while sparing adjacent organs. We therefore report the first series of patients with RPS treated solely with IMRT, surgery and chemotherapy. We hypothesized that IMRT would permit safe dose escalation and superior rates of local control (LC) in this high-risk patient population...
December 8, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29194633/systemic-therapy-in-retroperitoneal-sarcoma-management
#14
REVIEW
Anastasia Constantinidou, Robin L Jones
There is paucity of randomized controlled data on the role of systemic therapy in retroperitoneal sarcomas. The type of systemic therapy used is guided by the histological subtype. The majority of retroperitoneal sarcomas comprising liposarcomas and leiomyosarcomas are by and large chemotherapy insensitive. There is an urgent need for more efficacious systemic therapies in the management of early and advanced stage retroperitoneal sarcomas.
November 30, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29193249/turbocharged-bilateral-pedicled-diep-flap-for-reconstruction-of-thigh-defect-without-recipient-vessels-a-case-report
#15
Manuel Fernández Garrido, Nicolás Pereira, Susana López Fernández, Carmen Vega, Jaume Masià
Reconstruction of thigh defects is usually straightforward, but in cases of poor soft tissue quality, free flap reconstruction is not possible due to the absence of recipient vessels. The turbocharge technique may increase the viable, vascularized area of a flap. In this report we present a case of the use of a turbocharged bilateral pedicled DIEP flap for reconstruction of thigh defect without recipient vessels. A 29-year-old woman who underwent neoadjuvant chemotherapy plus radiation therapy for a leiomyosarcoma on the left thigh...
November 29, 2017: Microsurgery
https://www.readbyqxmd.com/read/29185261/pazopanib-monotherapy-in-the-treatment-of-pretreated-metastatic-uterine-sarcoma-a-single-center-retrospective-study
#16
Hyun Jun Kim, Youjin Kim, Su Jin Lee, Jeeyun Lee, Se Hoon Park
OBJECTIVE: In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy. We retrospectively investigated outcomes of pazopanib in patients with metastatic uterine STS. METHODS: A retrospective study was performed on 35 consecutive patients with uterine STS treated with oral pazopanib 800 mg daily as salvage therapy for metastatic disease between September 2013 and December 2015. Endpoints included response rate, survival, and safety...
January 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29176397/a-case-of-heavily-pretreated-metastatic-cardiac-angiosarcoma-treated-successfully-using-eribulin
#17
Chiaki Inagaki, Tatsunori Shimoi, Hitomi Okuma, Akiko Kitano, Akihiko Shimomura, Emi Noguchi, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Akihiko Yoshida, Yasuhiro Fujiwara, Kenji Tamura
Eribulin mesylate (eribulin) is a nontaxane microtubule inhibitor approved in Japan for treating soft tissue sarcoma irrespective of histological subtypes. Thus, our department routinely uses eribulin to treat any histological subtype of sarcoma for patients who have experienced disease progression during standard therapy. However, evidence on the efficacy of eribulin in treating sarcomas that are neither liposarcoma nor leiomyosarcoma is limited. Recently, we encountered a case of a heavily pretreated cardiac angiosarcoma that responded well to eribulin treatment...
January 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29137065/primary-leiomyosarcoma-of-the-bone-a-case-report-and-a-review-of-the-literature
#18
Federica Recine, Alberto Bongiovanni, Roberto Casadei, Federica Pieri, Nada Riva, Alessandro De Vita, Laura Mercatali, Chiara Liverani, Chiara Spadazzi, Giacomo Miserocchi, Valentina Fausti, Dino Amadori, Toni Ibrahim
RATIONALE: Leiomyosarcoma (LMS) is a malignant sarcoma that can occur in different anatomic sites, including the bone, showing similar histological characteristics but heterogeneous clinical behavior and prognosis. Primary bone LMS was first described in 1965. It is a very rare sarcoma, accounting for <0.7% of all primary malignant bone tumors. PATIENT CONCERNS: We report the case of a 52-year-old male with primary bone LMS who presented with a solitary osteolytic lesion with focal cortical destruction in the left clavicle, seen on an x-ray and subsequent computed tomography (CT) scan...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29100621/clinical-and-histopathologic-findings-of-cutaneous-leiomyosarcoma-correlation-with-prognosis-in-12-patients
#19
E Rodríguez-Lomba, I Molina-López, V Parra-Blanco, R Suárez-Fernández, A Pulido-Pérez
INTRODUCTION: Cutaneous leiomyosarcoma is a malignant neoplasm derived from smooth muscle cells. Its low incidence hampers the development of specific protocols for diagnosis and treatment. OBJECTIVES: To describe the clinical and histopathologic characteristics of a series of primary and secondary cutaneous leiomyosarcomas and to determine how these characteristics correlate with prognosis. MATERIAL AND METHODS: We performed an observational, descriptive, retrospective study based on 17 cutaneous leiomyosarcomas in 12 patients diagnosed between January 1, 2000 and December 31, 2015...
October 31, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/29097650/leiomyosarcoma-of-the-inferior-vena-cava-in-an-hiv-positive-adult-patient-a-case-report-and-review-of-the-literature
#20
Jing Xu, Arash Velayati, Barbara J Berger, Ming Liu, Naga K Sucharita Cheedella, Vladimir Gotlieb
BACKGROUND Leiomyosarcoma is the most common primary malignancy of the inferior vena cava (IVC), and represents approximately 10% of primary retroperitoneal sarcomas. Leiomyosarcoma presents with non-specific symptoms, including abdominal pain or back pain. There is an increased incidence in immunosuppressed individuals. CASE REPORT An unusual presentation of IVC leiomyosarcoma is reported in a 46-year-old female patient infected with human immunodeficiency virus (HIV) who was on highly active antiretroviral therapy (HAART) and who had a normal CD4 count of 934, who presented with back pain...
November 3, 2017: American Journal of Case Reports
keyword
keyword
115503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"